A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model

Hedwig M. Blommestein, Silvia G. R. Verelst, Saskia de Groot, Peter C. Huijgens, Pieter Sonneveld, Carin A. Uyl-de Groot

Research output: Contribution to journalArticleAcademicpeer-review

31 Citations (Scopus)
Original languageEnglish
Pages (from-to)198-208
JournalEuropean journal of haematology
Issue number2
Publication statusPublished - Feb 2016


  • bortezomib
  • cost-effectiveness analysis
  • lenalidomide
  • multiple myeloma
  • real-world data
  • registries
  • thalidomide

Cite this